Aleta Biotherapeutics

Aleta Biotherapeutics is an immuno-oncology company focused on transforming cell therapies to target a broad range of cancer indications, including currently difficult-to-treat solid tumors. Aleta Bio has developed a unique portfolio of multi-antigen targeting solutions for cell therapy, designed to address key challenges such as CAR-T persistence, tumor antigen loss leading to patient relapse, and tumor antigen heterogeneity. Co-founders Paul Rennert and Roy Lobb bring extensive scientific and leadership experience in immunology, oncology, and drug development to this new venture.